<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30313" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Beta-Blocker Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khalid</surname>
            <given-names>Muhammad M.</given-names>
          </name>
          <aff>Drexel Univ College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Galuska</surname>
            <given-names>Michael A.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hamilton</surname>
            <given-names>Richard J.</given-names>
          </name>
          <aff>Drexel University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Khalid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Galuska declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richard Hamilton declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30313.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Beta-blockers antagonize beta-adrenergic receptors and are used mainly in the treatment of hypertension, heart failure, tachydysrhythmias, and angina pectoris. In addition to cardiovascular disorders, beta-blockers are also used in the management of anxiety, migraine headache, glaucoma, tremor, hyperthyroidism, and various other disorders. The development of beta-blockers has revolutionized the management of cardiovascular disorders and they are known to provide morbidity and mortality benefits to patients with ischemic heart diseases. Beta-blockers prevent remodeling of the heart after an ischemic event by reducing the effects of catecholamines on cardiac tissue. This activity reviews the causes, pathophysiology and presentation of beta-blocker toxicity and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Discuss the pathophysiology of beta-blocker toxicity.</p></list-item><list-item><p>Discuss the evaluation of a patient with beta-blocker toxicity.</p></list-item><list-item><p>Summarize the treatment and management options available for beta-blocker toxicity.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to evaluate and treat beta-blocker toxicity and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30313&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30313">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30313.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Beta-blockers antagonize beta-adrenergic receptors and are used&#x000a0;mainly in the treatment of hypertension, heart failure, tachydysrhythmias, and angina pectoris. In addition to cardiovascular disorders, beta-blockers are also used in the management of anxiety, migraine headache, glaucoma, tremor, hyperthyroidism, and various other disorders. Propranolol is one of the earliest beta-blockers manufactured and has been in the United States since 1973. The development of beta-blockers has revolutionized the management of cardiovascular disorders and is known to&#x000a0;provide morbidity and mortality benefits to patients with ischemic heart diseases. Beta-blockers prevent remodeling of the heart after an ischemic event by reducing the effects of catecholamines on cardiac tissue. They are recommended for the treatment of congestive heart failure by the American College of Cardiology Foundation/American Heart Association Task Force.<xref ref-type="bibr" rid="article-30313.r1">[1]</xref><xref ref-type="bibr" rid="article-30313.r2">[2]</xref></p>
      </sec>
      <sec id="article-30313.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of beta-blocker overdose is closely related to the epidemiology of depression and the presence of&#x000a0;coexisting medical conditions that are treated with beta-blockers. In one study, patients who overdosed on beta-blockers were more likely to be women (3:1) with a mean age of 30 years. Two-thirds of these patients overdosed on someone else&#x02019;s medication or were using beta-blockers for noncardiac indications (e.g., migraine, tremor, thyrotoxicosis).<xref ref-type="bibr" rid="article-30313.r3">[3]</xref><xref ref-type="bibr" rid="article-30313.r4">[4]</xref><xref ref-type="bibr" rid="article-30313.r5">[5]</xref></p>
      </sec>
      <sec id="article-30313.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In 2015, According to the American Association of Poison Control Center (AAPCC) database, 10,577 single-exposure cases of beta-blockers were reported, 9.6% (1022) cases of which were coded to have moderate to the major outcome. Eighty-two percent (8706) of these exposures were unintentional. The trend of beta-blocker exposure from the National Poison Data System (NPDS) database reveals 118 more exposures in 2015 compared to 2014 but fewer (eight versus 14) fatal cases. Of all the beta-blockers, propranolol accounts for the majority of cases of beta-blocker toxicity.<xref ref-type="bibr" rid="article-30313.r6">[6]</xref></p>
      </sec>
      <sec id="article-30313.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Traditionally, beta-blockers are classified as selective and non-selective depending on the receptor specificity. Specificity is, however, lost in cases involving overdose. To better understand the toxicity,&#x000a0;beta-blockers&#x000a0;are classified as lipophilic or lipophobic. Highly lipophilic&#x000a0;beta-blockers&#x000a0;can easily cross the blood-brain barrier and may cause various central nervous system (CNS) manifestations. While CNS manifestations secondary to&#x000a0;beta-blocker&#x000a0;overdose are primarily attributed to lipophilicity, water-soluble&#x000a0;beta-blockers, for example,&#x000a0;atenolol, may also cause tiredness and fatigue. &#x000a0;</p>
        <p>Various metabolic and circulatory pathways are dependent on circulating catecholamine that, in turn, is switched off by beta-blockade. While hypotension, bradycardia, decreased myocardial contractility and oxygen consumption account for the hemodynamic instability, hypoglycemia secondary to inhibition of glycogenolysis and gluconeogenesis may also occur.</p>
      </sec>
      <sec id="article-30313.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Beta-blockers are readily absorbed when ingested with peak absorption within one to four hours except for sustained-release preparations. Absorption may also be delayed in cases involving the co-ingestion of drugs which can decrease gastrointestinal motility. While most of the&#x000a0;beta-blockers&#x000a0;are moderately lipophilic, certain beta-blockers have extensive lipophilicity and have a large volume of distribution. Propranolol, the most lipophilic&#x000a0;beta-blocker,&#x000a0;can easily cross the lipid cell and blood-brain barrier and may cause seizures in overdose cases.</p>
        <p>The liver excretes&#x000a0;beta-blockers&#x000a0;most&#x000a0;frequently. Atenolol, carteolol, and nadolol are the only exceptions that undergo renal excretion. Various&#x000a0;beta-blockers&#x000a0;may cause sodium or potassium channel blockade and therefore cause prolongation in QRS and QTc interval, respectively. Sodium channel blocking&#x000a0;beta-blockers&#x000a0;are said to possess &#x0201c;membrane stabilizing activity&#x0201d; which potentiates toxicity in overdose.</p>
      </sec>
      <sec id="article-30313.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Practitioners should&#x000a0;take a proper history regarding co-ingestions, particularly anticholinergics and cardiotoxic medications. Co-ingestion involving calcium channel blockers (CCB) may cause profound hypotension and cardiotoxicity. Various other cardiotoxic medications, for example, tricyclic antidepressants and antipsychotics, may potentiate&#x000a0;beta-blocker&#x000a0;toxicity. Underlying medical illnesses especially patients with underlying cardiac diseases are at increased risk of poor outcomes. Different&#x000a0;beta-blockers&#x000a0;have different half-lives that may range from several minutes to several hours. Therefore, efforts should be made to determine the exact beta-blocker involved.</p>
      </sec>
      <sec id="article-30313.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Bradycardia associated with hypotension may be the first clue to diagnose&#x000a0;beta-blocker&#x000a0;overdose. In comparison to calcium channel blocker overdose, which may mimic&#x000a0;beta-blocker&#x000a0;overdose, patients with BB toxicity have hypoglycemia and altered mental status. While symptoms secondary to&#x000a0;beta-blocker&#x000a0;overdose usually appear early and are commonly observed within one to two hours, the risk of toxicity is greatest up to 20 hours in cases involving sotalol toxicity. The QTc prolongation secondary to sotalol may prolong up to three to four days and may warrant close observation in a unit setting. Correctable causes of QTc prolongations should be investigated, and medications that may prolong QTc should be avoided. Sustained-release preparations and beta-blockers with longer half-lives may require extended monitoring. Vital signs should be monitored,&#x000a0;continuously&#x000a0;and 12 lead&#x000a0;EKG should be done at frequent intervals.<xref ref-type="bibr" rid="article-30313.r7">[7]</xref></p>
      </sec>
      <sec id="article-30313.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Due to intrinsic lipophilicity, certain beta-blockers may cause CNS depression. Prompt management of the airway is, therefore crucial. The airway should be protected with a cuffed endotracheal tube in all deeply obtunded patients. Premedication with atropine may be necessary especially in children since laryngeal manipulation during intubation may cause additive vagal stimulation and bradycardia. Bronchospasm due to beta-blockade may be treated with supplemental oxygen and inhaled bronchodilators like albuterol. Gastrointestinal decontamination with gastric lavage may be necessary for patients who present shortly after massive ingestions and/or with serious symptoms.</p>
        <p>Administer activated charcoal to limit drug absorption to patients with minor symptoms who present later than an hour after ingestion. Consider whole bowel irrigation with polyethylene glycol sustained-release preparation and continued until the rectal effluent is clear. Benzodiazepines are the first line of treatment for seizures that may occur due to the high lipophilicity of certain beta-blockers. Prompt recognition of QRS widening and prolongation of QTc interval is crucial.</p>
        <p>Administer sodium bicarbonate for QRS widening and magnesium sulfate for QTc prolongation. Although there have been no controlled trials to prove the efficacy of glucagon in poisoning beta-blocker overdose, glucagon is considered as a useful treatment of choice. Premedication with antiemetic may be considered since treatment with glucagon may induce vomiting.</p>
        <p>Other possible&#x000a0;side effects of glucagon include hypocalcemia and hyperglycemia. Treatment with calcium salts may provide benefits for hypotensive patients who overdosed on beta-blockers alone or in combination with a calcium channel blocker. Cases refractory to fluids, atropine, and glucagon should be considered candidates for high-dose insulin, euglycemia (HIE) treatment. High-dose insulin, euglycemia&#x000a0;is a safe and simple way to augment cardiac contractility and does not need invasive monitoring.&#x000a0;High-dose insulin, euglycemia&#x000a0;can cause profound hypokalemia and hypoglycemia that can potentiate the cardiotoxicity in the setting of beta-blocker overdose.</p>
        <p>Potassium and glucose should, therefore, be checked before initiation of high-dose insulin, euglycemia. In general, 1 U/kg of regular insulin bolus along with 0.5 g/kg dextrose intravenously (IV) is administered. Intravenous dextrose bolus should not be administered if the glucose level is more than 400 mg/dL.</p>
        <p>Glucose should be monitored every 30 mins initially for up to four hours to maintain strict glycemic control (glucose 100 mg/dL to 200 mg/dL) by starting 10% dextrose infusion and dextrose 50% IV boluses, as needed. Supportive treatment with vasopressors may be needed since the inotropic effect of high-dose insulin euglycemia&#x000a0;may be delayed up to 15 min to 60 min. The choice of vasopressor mainly depends on clinical findings. Phosphodiesterase such as inamrinone and milrinone increase the cAMP and may prove beneficial in increasing inotropy.</p>
        <p>Prompt initiation of ECMO and continuation of mechanical life support may be needed until the xenobiotic effect wears off. Toxicity secondary to water-soluble and renally excreted beta-blockers (e.g., acebutolol, atenolol, nadolol, and sotalol) may respond to enhanced elimination techniques such as multiple doses activated charcoal, hemoperfusion or hemodialysis.</p>
      </sec>
      <sec id="article-30313.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Antidepressant toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Carbamazepine toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac glycoside plant poisoning</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cocaine toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Epidural hematoma in emergency medicine</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyperkalemia in emergency medicine</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Meningitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Shock, cardiogenic</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Torsade de Pointes</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Toxicity, Calcium channel blockers</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30313.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Beta-blockers are one of the most commonly prescribed drugs for the treatment of various cardiac disorders, hyperthyroidism, migraine, glaucoma, and anxiety. Besides physicians, nurses and pharmacists need to be familiar with the therapeutic uses of these drugs and their toxicity. Over the years, the numbers of beta-blocker associated toxicity have&#x000a0;slightly increased, but the fatalities have decreased because&#x000a0;of prompt diagnosis and treatment. The outcomes after beta-blocker toxicity depend on when the patient presents and the amount ingested. Overall, the lipid-soluble beta-blockers are more toxic than the water-soluble&#x000a0;agents because of their quinidine-like effects. Individuals with underlying heart and lung disease are most susceptible to the toxic effects of beta-blockers. The outcomes are worse in people who are also consuming other cardioactive and psychotropic agents. When patients present with suspected beta-blocker toxicity, the patients should be admitted to the ICU, and a nephrologist should be consulted, in case dialysis is required. Any patient with an intentional overdose should be referred to a mental health counselor prior to discharge. <xref ref-type="bibr" rid="article-30313.r5">[5]</xref><xref ref-type="bibr" rid="article-30313.r8">[8]</xref>(Level V)</p>
      </sec>
      <sec id="article-30313.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30313&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30313">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/beta-blocker-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30313">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30313/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30313">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30313.s13">
        <title>References</title>
        <ref id="article-30313.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krenz</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kaakeh</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>An Overview of Hyperinsulinemic-Euglycemic Therapy in Calcium Channel Blocker and &#x003b2;-blocker Overdose.</article-title>
            <source>Pharmacotherapy</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>1130</fpage>
            <page-range>1130-1142</page-range>
            <pub-id pub-id-type="pmid">30141827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30313.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griswold</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Blohm</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Unsuspected Clenbuterol Toxicity in a Patient Using Intramuscular Testosterone.</article-title>
            <source>Clin Pract Cases Emerg Med</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>197</fpage>
            <page-range>197-200</page-range>
            <pub-id pub-id-type="pmid">29849287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30313.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walter</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McKinlay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kirk-Bayley</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Review of management in cardiotoxic overdose and efficacy of delayed intralipid use.</article-title>
            <source>J Intensive Care Soc</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-55</page-range>
            <pub-id pub-id-type="pmid">29456602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30313.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Laurin</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Albertson</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Metoprolol treatment of dual cocaine and bupropion cardiovascular and central nervous system toxicity.</article-title>
            <source>Clin Exp Emerg Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-88</page-range>
            <pub-id pub-id-type="pmid">29381909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30313.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maharaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seegobin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Perez-Downes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bajric</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Severe carvedilol toxicity without overdose - caution in cirrhosis.</article-title>
            <source>Clin Hypertens</source>
            <year>2017</year>
            <volume>23</volume>
            <fpage>25</fpage>
            <pub-id pub-id-type="pmid">29214053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30313.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menke</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Cardiotoxicodynamics: Toxicity of Cardiovascular Xenobiotics.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>563</fpage>
            <page-range>563-95</page-range>
            <pub-id pub-id-type="pmid">26226867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30313.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Beta-blocker and calcium channel blocker toxicity.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>1994</year>
            <month>May</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>365</fpage>
            <page-range>365-90</page-range>
            <pub-id pub-id-type="pmid">7910555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30313.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wells</surname>
                <given-names>QS</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Roden</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Genetic determinants of response to cardiovascular drugs.</article-title>
            <source>Curr Opin Cardiol</source>
            <year>2012</year>
            <month>May</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-61</page-range>
            <pub-id pub-id-type="pmid">22382501</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
